{"disease":{"id":"prostate-ca","name":"prostate ca"},"drugs":{"marketed":[{"drug_id":"olaparib","indication_name":"Hormone refractory prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynparza","generic_name":"olaparib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor [EPC]","quality_score":73,"revenue":"2600","mechanism":"Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP."},{"drug_id":"apalutamide","indication_name":"Castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erleada","generic_name":"apalutamide","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"","quality_score":65,"revenue":"2600","mechanism":"Erleada blocks the androgen receptor, a protein that helps cancer cells grow."},{"drug_id":"talazoparib-with-enzalutamide","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talazoparib with enzalutamide","generic_name":"talazoparib-with-enzalutamide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP enzymes and androgen receptor","drug_class":"PARP inhibitor and androgen receptor inhibitor","quality_score":10,"revenue":"2194","mechanism":""},{"drug_id":"darolutamide","indication_name":"Hormone refractory prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"darolutamide","indication_name":"Metastatic castration-sensitive prostate cancer (mCSPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"darolutamide","indication_name":"Metastatic prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"darolutamide","indication_name":"Metastatic castration-sensitive prostate cancer (mCSPC) with docetaxel","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"darolutamide","indication_name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"abiraterone","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"abiraterone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CYP17","drug_class":"Androgen biosynthesis inhibitor","quality_score":67,"revenue":"1500","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells."},{"drug_id":"abiraterone","indication_name":"Metastatic high-risk castration-sensitive prostate cancer (mHSPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"abiraterone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CYP17","drug_class":"Androgen biosynthesis inhibitor","quality_score":67,"revenue":"1500","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells."},{"drug_id":"abiraterone-acetate","indication_name":"Metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zytiga","generic_name":"abiraterone-acetate","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Steroid 17-alpha-hydroxylase/17,20 lyase","drug_class":"Cytochrome P450 17A1 Inhibitor","quality_score":64,"revenue":"1500","mechanism":"Zytiga blocks the production of male hormones that fuel prostate cancer growth."},{"drug_id":"abiraterone","indication_name":"Chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"abiraterone","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CYP17","drug_class":"Androgen biosynthesis inhibitor","quality_score":67,"revenue":"1500","mechanism":"Abiraterone is an androgen biosynthesis inhibitor that targets CYP17 to reduce androgen production in prostate cancer cells."},{"drug_id":"niraparib","indication_name":"Hormone refractory prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zejula","generic_name":"niraparib","company_name":"GSK","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor","quality_score":69,"revenue":"600","mechanism":"Zejula works by blocking the action of an enzyme called PARP, which helps repair damaged DNA in cancer cells."},{"drug_id":"radium-223","indication_name":"Castration-Resistant Prostate Cancer, Bone Metastases","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Radium-223","generic_name":"radium-223","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bone cells","drug_class":"Radiopharmaceutical","quality_score":50,"revenue":"400","mechanism":""},{"drug_id":"tetraxetan","indication_name":"metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"TETRAXETAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":10,"revenue":"386","mechanism":"Pluvicto works by binding to the PSMA protein on prostate cancer cells, delivering a radioactive payload to destroy the cancer cells."},{"drug_id":"tetraxetan","indication_name":"metastatic castration-resistant prostate cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"TETRAXETAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":10,"revenue":"386","mechanism":"Pluvicto works by binding to the PSMA protein on prostate cancer cells, delivering a radioactive payload to destroy the cancer cells."},{"drug_id":"lutetium-177lu-vipivotide-tetraxetan","indication_name":"PSMA-positive metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pluvicto","generic_name":"Lutetium (177Lu) vipivotide tetraxetan","company_name":"Aaa Usa Novartis","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"Radioligand Therapeutic Agent [EPC]","quality_score":45,"revenue":"386","mechanism":"Pluvicto works by binding to prostate-specific antigen (PSMA) on cancer cells, delivering a radioactive payload that kills the cells."},{"drug_id":"jevtana","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Jevtana","company_name":"Bayer","drug_phase":"discontinued","molecular_target":"Tubulin beta","drug_class":"","quality_score":null,"revenue":"300","mechanism":""},{"drug_id":"cabazitaxel","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jevtana Kit","generic_name":"cabazitaxel","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"Tubulin beta","drug_class":"Microtubule Inhibitor","quality_score":80,"revenue":"300","mechanism":"Cabazitaxel works by binding to tubulin beta, disrupting microtubule formation and preventing cancer cell division."},{"drug_id":"talzenna","indication_name":"HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"Talazoparib Tosylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PARP1 and PARP2 enzymes","drug_class":"PARP inhibitor","quality_score":75,"revenue":"182","mechanism":"PARP1/PARP2 inhibitor causing DNA damage, decreased proliferation, and apoptosis in BRCA-mutated cancers."},{"drug_id":"mitozantrone","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mitozantrone","company_name":"US Department of Veterans Affairs","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bicalutamide","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Casodex","generic_name":"bicalutamide","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Casodex works by blocking the androgen receptor, a protein that helps prostate cancer cells grow."},{"drug_id":"sipuleucel-t","indication_name":"Metastatic castrate-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SIPULEUCEL-T","company_name":"","drug_phase":"marketed","molecular_target":"PAP","drug_class":"Autologous Cellular Immunotherapy [EPC]","quality_score":10,"revenue":null,"mechanism":"PROVENGE induces an immune response against PAP, an antigen found in most prostate cancers."},{"drug_id":"sipuleucel-t","indication_name":"Metastatic castrate-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SIPULEUCEL-T","company_name":"","drug_phase":"marketed","molecular_target":"PAP","drug_class":"Autologous Cellular Immunotherapy [EPC]","quality_score":10,"revenue":null,"mechanism":"PROVENGE induces an immune response against PAP, an antigen found in most prostate cancers."},{"drug_id":"chembl-chembl3183409","indication_name":"Metastatic castration-sensitive prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"APALUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen Receptor (AR)","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Apalutamide binds to the androgen receptor, blocking its function and reducing tumor growth."},{"drug_id":"chembl-chembl3183409","indication_name":"Non-metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"APALUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen Receptor (AR)","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Apalutamide binds to the androgen receptor, blocking its function and reducing tumor growth."},{"drug_id":"mitoxantrone","indication_name":"Advanced Hormone-Refractory Prostate Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"chembl-chembl409","indication_name":"Stage D2 Metastatic Prostate Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BICALUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"estradiol-valerate","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Delestrogen","generic_name":"ESTRADIOL VALERATE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":65,"revenue":null,"mechanism":"Delestrogen works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"estradiol","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"nilutamide","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nilandron","generic_name":"NILUTAMIDE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"casodex","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Casodex","company_name":"University Health Network, Toronto","drug_phase":"discontinued","molecular_target":"Cytochrome P450 2C19, Androgen receptor, Androgen receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl254328","indication_name":"Metastatic castration-resistant prostate cancer (CRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"ABIRATERONE","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":42,"revenue":null,"mechanism":"Abiraterone Acetate blocks the production of androgens, which are hormones that prostate cancer cells need to grow."},{"drug_id":"chembl-chembl254328","indication_name":"Metastatic high-risk castration-sensitive prostate cancer (CSPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abiraterone Acetate","generic_name":"ABIRATERONE","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":42,"revenue":null,"mechanism":"Abiraterone Acetate blocks the production of androgens, which are hormones that prostate cancer cells need to grow."},{"drug_id":"mitoxantrone","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"estring","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"lynparza","indication_name":"Hormone refractory prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lynparza","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Mono [ADP-ribose] polymerase PARP16, Tankyrase-1, Tankyrase-2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"zytiga","indication_name":"Metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zytiga","company_name":"Bukwang Pharmaceutical","drug_phase":"marketed","molecular_target":"Cytochrome P450 11B2, mitochondrial, Androgen receptor, Cytochrome P450 11B1, mitochondrial","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"estradiol-cypionate","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depoestradiol","generic_name":"ESTRADIOL CYPIONATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"flotufolastat","indication_name":"prostate cancer with suspected metastasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Posluma","generic_name":"FLOTUFOLASTAT","company_name":"Blue Earth","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":60,"revenue":null,"mechanism":"Posluma works by emitting radiation that helps doctors visualize and diagnose prostate cancer."},{"drug_id":"pluvicto","indication_name":"PSMA-positive metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pluvicto","company_name":"VA Office of Research and Development","drug_phase":"marketed","molecular_target":"Prostate-specific antigen","drug_class":"","quality_score":11,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"olaparib-oral-product","indication_name":"Advanced prostate adenocarcinoma with neuroendocrine differentiation","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."},{"drug_id":"oligomeric-procyanidin-complex","indication_name":"Prostate cancer prevention (AGE manipulation)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oligomeric Procyanidin Complex","company_name":"Medical University of South Carolina","drug_phase":"discontinued","molecular_target":"Advanced glycation end products (AGEs), free radicals, inflammatory mediators","drug_class":"Botanical antioxidant, polyphenol","quality_score":null,"revenue":null,"mechanism":"Oligomeric procyanidins are plant-derived polyphenols that exert antioxidant and anti-inflammatory effects, potentially inhibiting advanced glycation end product formation."},{"drug_id":"lutetium-177","indication_name":"Metastatic Castration Sensitive Prostate Cancer (mCSPC)","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lutetium-177","generic_name":"lutetium-177","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"mCRPC","quality_score":null,"revenue":null,"mechanism":"mCRPC"}],"offLabel":[],"totalMarketed":41,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT04334239","title":"Effectiveness of Care in Certified Cancer Centres in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":670000,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT04290611","title":"a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY","phase":"","overall_status":"COMPLETED","enrollment_count":500000,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT07206693","title":"Impact of PSA-based Screening on Mortality Among Men Aged 75-79: Target Trial Emulation","phase":"","overall_status":"COMPLETED","enrollment_count":257275,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT03896178","title":"Prostate Cancer in Firemen: Early Diagnosis Because of Increased Diagnostic Pressure?","phase":"","overall_status":"COMPLETED","enrollment_count":137536,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT04047329","title":"Risk Factors and Impact of Anesthesia Techniques on Myocardial Infarction Following Transurethral Resection of the Prostate","phase":"","overall_status":"COMPLETED","enrollment_count":115025,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT06043947","title":"Survival Monitoring in Russian Cancer Registries","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"N.N. Petrov National Medical Research Center of Oncology","has_results":false},{"nct_id":"NCT00352924","title":"Agriculture Health Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":89655,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04587284","title":"Economic Evaluation of Robot-assisted Laparoscopic Radical Prostatectomy vs Conventional Laparoscopic Radical Prostatectomy and Open Retropubic Radical Prostatectomy in Prostate Cancer: a Real-life Study Based on the French National Healthcare Data System (SNDS)","phase":"","overall_status":"UNKNOWN","enrollment_count":84667,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT02044172","title":"Prostate Testing for Cancer and Treatment","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":82849,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT00002540","title":"Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":76685,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07328516","title":"Natural History Study of Early Life Exposures in Agriculture (ELEA)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":64277,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06902441","title":"Impact of New Hormonotherapy Drugs in Prostatic Cancer on the Risk of Cardiovascular Events : a Pharmacoepidemiology Study Using the French Health Care Claims Database","phase":"","overall_status":"COMPLETED","enrollment_count":52000,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT07109427","title":"Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System","phase":"NA","overall_status":"RECRUITING","enrollment_count":40000,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT02895230","title":"Androgen-Deprivation Therapy and Cardiovascular Risk: A Nationwide Population-based Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":38690,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT05961514","title":"the Beijing Randomized Study Of Prostate Cancer Screening","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30000,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT06995898","title":"The Vanguard Study: Testing a New Way to Screen for Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":24000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06424275","title":"Prostate Cancer Awareness and Initiative for Screening in the European Union","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":20000,"lead_sponsor_name":"European Association of Urology Research Foundation","has_results":false},{"nct_id":"NCT06397755","title":"Observational Study of Patients Who Underwent Diagnostic Investigation (Prostate Biopsy) and/or Radical Prostatectomy Surgery.","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT00026754","title":"Eligibility Screening for the NIH Intramural Research Program Clinical Protocols","phase":"","overall_status":"COMPLETED","enrollment_count":19522,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03423303","title":"A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":17400,"lead_sponsor_name":"Tampere University","has_results":false},{"nct_id":"NCT00060476","title":"Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":15000,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06714630","title":"The PROSECCA Study, Answering New Questions in Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT03344835","title":"Hong Kong Prostate Cancer Study Group Database","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT03871816","title":"A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":14532,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04897958","title":"Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":14417,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05384002","title":"An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum","phase":"","overall_status":"COMPLETED","enrollment_count":14000,"lead_sponsor_name":"Fondazione del Piemonte per l'Oncologia","has_results":false},{"nct_id":"NCT05202301","title":"A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely","phase":"","overall_status":"COMPLETED","enrollment_count":13779,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03381105","title":"From PSA to Stockholm3: Study Part 1","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13431,"lead_sponsor_name":"Helse Stavanger HF","has_results":false},{"nct_id":"NCT03377881","title":"Prostate Cancer Detection Using the Stockholm3 Test and MR/Fusion Biopsies","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12750,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT00340600","title":"Continuation of Follow-up of DES-Exposed Cohorts","phase":"","overall_status":"COMPLETED","enrollment_count":10805,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05489341","title":"Artificial Intelligence and Radiologists at Prostate Cancer Detection in MRI: The PI-CAI Challenge","phase":"","overall_status":"COMPLETED","enrollment_count":10207,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT03914391","title":"To Identify Potential New Urine Markers for the Screening of Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT06366308","title":"Decade-Long Insights Into Transperineal Prostate Biopsy in a West China Population","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT03948204","title":"Quality of Life and Shared Decision Making in Prostate Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Norwegian Institute of Public Health","has_results":false},{"nct_id":"NCT06320223","title":"PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT04034953","title":"Prevention of Obesity-related Cancers: Setting up of a Multi-Cancer Education and Prevention Program in Hong Kong","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT03354416","title":"Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04075305","title":"The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT00001469","title":"Genetic Analysis of Hereditary Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":7776,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT03619980","title":"A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the Disease Trajectories Until Progression or Death","phase":"","overall_status":"COMPLETED","enrollment_count":6908,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07450157","title":"A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617","phase":"","overall_status":"COMPLETED","enrollment_count":6448,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06717295","title":"The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Javier Toledo","has_results":false},{"nct_id":"NCT06440018","title":"INSPIRE: a Multi-Cancer Early Detection Study","phase":"","overall_status":"RECRUITING","enrollment_count":5350,"lead_sponsor_name":"Singlera Genomics Inc.","has_results":false},{"nct_id":"NCT03662204","title":"Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":5133,"lead_sponsor_name":"Exact Sciences Corporation","has_results":false},{"nct_id":"NCT00342784","title":"Identification of Prostate Cancer Genes","phase":"","overall_status":"COMPLETED","enrollment_count":5118,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT05926102","title":"The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)","phase":"NA","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT05078359","title":"Optimizing Positive Predicting Value of Prostate MRI","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Ospedali Riuniti di Foggia","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}